Emerging therapies, such as sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, offer cardioprotective and renoprotective benefits in broader populations; however, their efficacy in FD remains poorly studied. The gene discussed is SLC5A2; the disease is Fabry disease.